Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3

Leukemia

Volumn 22, Issue 2, 2008, Pages 393-399

  Booken, N ^a   Gratchev, A ^a   Utikal, J ^a   Weiss C ^a   Yu, X ^a   Qadoumi, M ^a   Schmuth, M ^b   Sepp, N ^b   Nashan, D ^c   Rass, K ^d   Tuting T ^e   Assaf, C ^f   Dippel, E ^a,g   Stadler, R ^h   Klemke, C D ^a   Goerdt, S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF FREIBURG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Department of Dermatology   (Germany)

^h Department of Dermatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYSTEINE DIOXYGENASE; DYNAMIN III; ONCOPROTEIN; PLASTIN 3; PROTEIN C MYB; SOMATOMEDIN; TAURINE; TRANSCRIPTION FACTOR TWIST; TUMOR NECROSIS FACTOR; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRAIT; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYCOSIS FUNGOIDES; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY SYNDROME; SKIN INFLAMMATION; UPREGULATION;

EID: 39149143027     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405044     Document Type: Article

References (23)

1. Dippel E, Goerdt S, Assaf C, Stein H, Orfanos CE. Cutaneous T-cell lymphoma severity index and T-cell gene: Rearrangement. Lancet 1997; 350: 1776-1777.
2. Klemke CD, Mannsmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005; 153: 118-124.
3. Dippel E, Assaf C, Hummel M, Schrag HJ, Stein H, Goerdt S et al. Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: A critical evaluation.J Pathol 1999; 188: 146-154.
4. Dippel E, Klemke D, Hummel M, Stein H, Goerdt S. T-cell clonality of undetermined significance. Blood 2001; 98: 247-248.
5. Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-1129.
6. Poszepczynska-Guigne E, Schiavon V, D'Incan M, Echchakir H, Musette P, Ortonne N et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: Relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol 2004; 122: 820-823.
7. Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S et al Quantitative PCR on 5 genes reliably identifies CTCL patients with 5-99% circulating tumor cells with 90% accuracy. Blood 2006; 107: 3189-3196.
8. Chu TM, Weir B, Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002; 176: 35-51.
9. Allison PD. Logistic Regression Using SAS System: Theory and Application. SAS Institute Inc.: Cary, NC, 1999, Chapter 2 and 3:4-78.
10. Wald A. Tests of statistical hypotheses concerning several paramet6s when the number of observations is large. Trans Amer Math Soc 1943; 54: 426-482.
11. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C et al Classificatioh and prediction of survival in patients with the leukemic phase of cutaneous T cells lymphoma. J Exp Med 2003; 197: 1477-1488.
12. Su MW, Dorocicz I; Dragowska WH, Hc V, Li G, Voss N et al. Aberrant expression of T-plastin in Sezary cells. Cancer Res 2003; 63: 7122-7127.
13. Van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64: 5578-55586.
14. Hahtola S, Tuomela S, Elo L, Hakkinen T, Karenko L, Nedoszytko B et al. Th1 response and cytotexicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res 2006; 12: 4812-4821.
15. Maher SG, Condron CE, Bouchier-Hayes DJ, Toomey DM. Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD). Clin Exp Immunol 2005; 139: 279-286.
16. Takatani T, Takahashi K, Uozumi Y, Shikata E, Yamamoto Y, Ito T et al Taurine inhibits apoptosis by preventing formation of the Apaf-1/ caspase-9 apoptosome. Am J Physiol Cell Physiol 2004; 287: C949-C953.
17. Ozgen U, Savasan S, Stout M, Buck S, Ravindranath Y. Further elucidation of mechanism of resistance to vincristine in myeloid cells: Role of hypochlorous-acid in degradation of vincristine by myeloperoxidase. Leukemia 2000; 14: 47-51.
18. Ramsden DB, Kapadi A, Fitch NJ, Farmer MJ, Bennett P, Williams AC. Human cysteine dioxygenase type I (CDO-I; EC 1.13.11.20): 5′ flanking region and intron-exon structure of the gene. Mol Pathol 1997; 50: 269-271.
19. Poenitz N, Simon-Ackermann J, Gracthev A, Qadoumi M, Klemke CD, Stadler R et al. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma. Dermatology 2005; 211 84-92.
20. Loebel DA, Tsoi B, Wong N, Tam PP. A conserved noncoding intronic transcript at the mouse Dnm3 locus. Genomics 2005; 85: 782-789.
21. Li CM, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H et al PEG10 is a c-MYC target gene in cancer cells. Cancer Res 2006; 66: 665-672.
22. Lin CS, Lau A, Huynh T, Lue TF. Differential regulation of human T-plastin gene in leukocytes; and non-leukocytes: Identification of the promoter, enhancer, and CpG island. DNA Cell Biol 1999; 18: 27-37.
23. Aliahmad P, O'Flaherty E, Han P, Goularte OD, Wilkinson B, Satake M et al. TOX provides a link between calcineurin activation and CD8 lineage commitment. J Exp Med 2004; 199: 1089-1099.